Health‐related quality of life · schoolchildren with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · schoolchildren with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · schoolchildren with CSOM
1 finding from 1 review
Serious complications · schoolchildren with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Suspected ototoxicity · schoolchildren with CSOM
1 finding from 1 review
Health‐related quality of life · children with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ear pain (otalgia) or discomfort or local irritation · children with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · children with CSOM
1 finding from 1 review
Serious complications ‐ during 6 months of · children with CSOM
1 finding from 1 review
Suspected ototoxicity · children with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of ear discharge ‐ measured at 1 to 2 weeks · people (of any age) with CSOM
Systemic antibiotics showed no clear difference in resolution of ear discharge ‐ measured at 1 to 2 weeks compared with no treatment or placebo on top of topical antibiotics (low certainty).
1 finding from 1 review
Resolution of ear discharge ‐ measured after 4 weeks · people (of any age) with CSOM
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Avoidance of surgery ‐ patients still meeting the criteria for surgery At end of · patients with severe chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review